Experts Warn $20,000 Autism Stem Cell Infusions Endanger Children as RFK Jr. Backs Unproven Clinics
Updated
Updated · streamlinefeed.co.ke · Jun 12
Experts Warn $20,000 Autism Stem Cell Infusions Endanger Children as RFK Jr. Backs Unproven Clinics
3 articles · Updated · streamlinefeed.co.ke · Jun 12
Summary
$20,000 per session autism stem cell infusions are spreading in U.S. clinics, with medical experts warning they expose children as young as 18 months to unproven and potentially severe harm.
A 180-child Duke University placebo-controlled trial found no meaningful behavioral benefit for most children, undercutting clinic claims that umbilical cord stem cells improve speech, socialization or aggression.
FDA warnings cite catastrophic complications from unregulated stem cell products, including tumors, systemic infections and blindness, while some clinics sedate children with drugs such as ketamine before infusions.
Robert F. Kennedy Jr.'s public support for alternative providers and his administration's cuts to federal health and autism research have, critics say, weakened oversight and encouraged a fast-growing market built on parental desperation.
With federal oversight weakening, who now protects families from the high cost and false hope of unproven stem cell autism treatments?
Clinics promise stem cell miracles for autism. What does science actually say about the real risks and benefits for children?
Unproven Hope or Medical Risk? The 2026 Tijuana Autism Stem Cell Trial and Its Impact on US Regulation
Overview
A major clinical trial on stem cell therapy for autism is set to begin in Tijuana, Mexico, in July 2026, led by Tracy Slepcevic and Ed Clay. Ed Clay, who turned to alternative treatments after a sports injury, transformed a disused hospital into the Cellular Performance Institute (CPI), now offering stem cell therapies for various conditions and serving as the official provider for the UFC. The trial aims to test stem cell treatments for autism, and if early results are promising, organizers hope to expand the study to the United States under full FDA licensing, potentially shaping future autism therapies.